EndoPredict®
Prognostic and predictive molecular in vitro test to determine the risk of recurrence and the absolute benefit of chemotherapy over the next 15 and 10 years, respectively, in patients with ER+/HER2- primary breast cancer.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.